A method for the treatment of colibacillosis and salmonellosis in pigs
The invention relates to the field of veterinary medicine. The invention solves the problem of increasing therapeutic effect in the treatment of infectious gastrointestinal disease in piglets: colibacillosis and salmonellosis. The method includes the introduction of Miramistin in a 0.01% aqueous solution. The drug is injected inside twice daily at a dose of 8-10 ml for 5-6 days. The method is effective for the treatment of colibacillosis and salmonellosis in pigs.
The invention relates to the field of veterinary medicine, in particular to methods of treatment of enteroenteric in piglets.
Anteroinferior young farm animals are one of the problematic pathologies in all countries of the world, their distribution is global in nature (1, 2).
There is a method of treatment of colibacillosis and salmonellosis in pigs by enteral and parenteral introduction of various drugs, mainly antibiotics, sulfonamides, nitrofuranov, metasystematic drugs (1, 5).
However, their application along with low efficiency, immunological depression and the creation of drug resistance in Salmonella and Asherah is employed, the problem of disease control animals.
The invention solves the problem of increasing therapeutic effect in the treatment of infectious gastrointestinal disease in piglets: colibacillosis and salmonellosis.
This is achieved in that in the method for the treatment of colibacillosis and salmonellosis in pigs by enteral introduction to animals of therapeutic drug according to the invention as a therapeutic substance used Miramistin in a 0.01% aqueous solution. The drug is injected inside twice daily at a dose of 8-10 ml of the pig within 5-6 days.
Miramistin - 0,01% transparent aqueous solution containing ministerialdirigent ammonium chloride, a cationic surfactant, no odor. Drug activity is not reduced when stored under normal conditions, it is resistant to boiling.
The basis of the biological actions of Miramistin is the impact on the cell membrane of bacterial cells. The predominant mechanism is the hydrophobic interaction Miramistin with the lipid membranes of microorganisms, leading to their fragmentation and destruction. The basis of the immunomodulating effect of Miramistin is the increased permeability of the membranes of immune cells (lymphocytes), which leads to the launching of human and animal cells, because they, unlike membrane of bacterial cells, have a significantly greater length of lipid radicals and hydrophobic interactions with molecules Miramistin does not occur.
Miramistin has a comprehensive antibacterial, antimycotic, antiviral, anti-inflammatory and simultaneously immunomodulatory effect. This unique combined action of the product fully meets therapeutic tactics in infectious gastrointestinal diseases of pigs.
Miramistin (0,01% aqueous solution) has a pronounced activity in the treatment of various diseases in humans (surgery, obstetrics, dentistry, combustology and others), mastitis in cows caused or complicated by gram-positive and gram-negative bacteria, pathogenic fungi, both in monocultures and their associations (3, 4). He has no local irritating action and has no allergenic, carcinogenic and mutagenic properties. The drug belongs to toxic substances (class 4).
Miramistin characterized by a broad spectrum of antimicrobial action. The range of its inhibitory effect against pathogenic cultures of Escherichia and Salmonella, leased the activity.
The proposed method is as follows. After diagnosis of colibacteriosis or salmonellosis Miramistin set individually for each animal inside in a 0.01% aqueous solution. The drug is administered at a dose of 8-10 ml of the pig 2 times a day for 5-6 days.
The use of Miramistin helps to normalize body temperature, improve the General condition of the animals, to increase appetite. Cessation of diarrhoea observed after 2-3 enteral prescriptions. Within 8-10 days after treatment in piglets are optimizing the composition of the blood, characterized by increased levels of leukocytes, erythrocytes, hemoglobin, and increased indices of cellular and humoral immunity.
When tested Miramistin therapeutic purposes colibacteriosis and salmonellosis in pigs disadvantaged farms safety of animals was 90-100% in the experimental groups. In the groups of control animals treated with chloramphenicol, recovery occurred more slowly, the safety of piglets was 65-70%.
Sources of information
1. Voronin E. C. Application of Immunostimulants and probiotics in diseases of the young. // Abstracts of the. - Kursk, 1996. - S. 82-84.
2. Jupina S. I. Epizootic process and its control in factorial infectious diseases. - Moscow, 2002. - S. 56-70.
3. Kuzmin, N., Whistles centuries, Skogoreva A. M., Loginov P. O. method for the treatment of subclinical mastitis in cows. Patent for invention No. 2180221. - Moscow, 2002. - 8 S.
4. Register of medicines of Russia “encyclopedia of drugs”. Ed. 6-E. - M.: “radar - 2000”, 1999. - S. 656. Miramistin.
5. Urban, B. N., Naiman, I. L. Diseases of young animals in the cattle industry. - L., 1985. - S. 124-133.
A method for the treatment of colibacillosis and salmonellosis in pigs by enteral introduction of medicinal substances, characterized in that as a therapeutic substance used Miramistin in a 0.01% aqueous solution, which is injected to the animal twice a day at a dose of 8-10 ml for 5-6 days.
in which Y denotes a hydrogen atom or fluorine; n denotes an integer from 1 to 8; Z represents a hydrogen atom or a residue of carboxylic acid, and in which pyrazol cycle substituted heteroaryl radical, which contains one nitrogen atom; and their salt adducts with tilotama
where R1and R2- substituents, which may represent amino acids, derivatives of amino acids, peptides, consisting of 1-15 amino acid residues, derived peptides consisting of 1-15 amino acid residues, and-carboxyl group of amino acids or peptides and side groups of amino acids or peptides can be modified, and it is possible that R1=R2or R1R2=OH; carboxyl group of the porphyrin can be modified methyl or other C2-C8-ester or a physiologically acceptable salt; Y-represents Cl-CH3SOO-; Me represents Fe, with the exception of compounds where
R1=-LeuLeuValPheOMe, R2=-OH; R1=-ValPheOMe, R2=-OH; R1=-LeuHisOMe,
R2=-OH; R1=-LeuHisAlaOMe, R2=-OH; R1=-LeuHisNHC10H20COOMe, R22=-LeuHisNHC10H20COOMe; R1=-Lys(Tfa)AlaAlaOMe, R2=-OH;
R1=-ValPheOMe, R2=-LeuHisOMe; R1=-LeuLeuValPheOMe, R2=-LeuHisOMe;
R1=-LeuLys(Tfa)LeuOMe, R2=-OH; R1=-LeuLys(Tfa)LeuOMe, R2=-LeuHisOMe;
R1=-Lys(Tfa)AlaAlaOMe, R2=-AlaHisLys(Cbz)LeuOMe; R1=-GlyOBzl,
R2=-GlyOBzl; R1=-HisOMe, R2=-HisOMe; R1=-LeuHisOMe, R2=-LeuHisOMe;
R1=-LeuHisOMe, R2=-OEt; R1=-LeuHisLeuGlyCys(Bzl)OBzl, R2=-OEt; R1=-OBzl,
R2=-OBzl; R1=-OBzl, R2=-OH; R1=-AlaOMe, R2=-OBzl; R1=-HisOMe, R2=-OBzl;
R1=-LeuHisOMe, R2=-OBzl; R1=-LeuHisLeuGlyCys(Bzl)OBzl, R2=-OBzl;
R1=-LeuHisAlaLys(Cbz)GlyCys(Bzl)OBzl, R2=-OBzl; R1=-LeuHisLys(Cbz)OMe,
R2=-OH; R1=-LeuHis(Bzl)Lys(Cbz)OMe, R2=-OH; R1=-LeuHisOMe, R2=-OMe;
R1=-LeuHis(Bzl)Lys(Cbz)OMe, R2=-OMe; R1=-AlaLeuAlaPheAlaCys(Bzl)OMe,
R2=-LeuHis(Bzl)Lys(Cbz)OMe; R1=-LeuHisOMe, R2=-OMe;
two ways to get hemin derivatives of General formula I, hemin derivatives of the formula I, formerly known above, as inhibitors of proteolytic enzymes: the HIV protease, pepsin, trypsin, chymotrypsin